Official Communication

April 8, 2026

MEDVi statement in response to external speculation

FDA letter

 In September 2025 and February 2026, the FDA sent an unprecedented number of warning letters to dozens of telehealth companies, drug companies and pharmacies regarding their direct-to-consumer advertising practices. In one of the FDA's letters, the URL mentioned is medvi.io - not MEDVi's actual address of medvi.org.

The letter addressed to MEDVi was directed at an affiliate marketing agency whose website contained outdated copy.

We immediately reached out to the affiliate and required them to remove the materials allegedly at issue. We understand the affiliate also directly responded to the FDA. 

My company MEDVi has never received a letter from the FDA. If we were to receive such a communication from any regulatory authority, we would act swiftly and collaboratively to address the matter.

So-called "fake doctors" 

We have recently become aware of what appear to be advertisements featuring potentially AI-generated medical practitioners.

Since we became aware of this issue, we have updated our marketing practices to make clear that this type of advertising and / or promotion is prohibited. We continue to proactively address this issue.

Additional statement from Mr. Gallagher

Building a company the size of MEDVi and scaling so quickly involves many learning moments. At each of these stages, I have course-corrected immediately and appropriately. I will continue to do so.

The New York Times was recently given unprecedented access to MEDVi's business information and also interviewed our business partners and other collaborators. 

As I continue helping our customers achieve their health goals, I remain committed to building and operating transparently.